Drug-Linker Conjugates for ADC

Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.

SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.

VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.

Mal-PEG4-Val-Cit-PAB-MMAE is the linker-payload component of an antibody-conjugated active molecule (ADC), consisting of a degradable ADC linker and the microtubule inhibitor MMAE.

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

CL2A-SN-38 consists of a CL2A linker and an anticancer compound, SN-38, which delivers active molecules within tumor cells and in the tumor microenvironment, often in conjunction with antibodies to make biologically active antibody-coupled reactive molecules (ADCs).

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of action.

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.

Vc-MMAD, a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), combines the ADC linker Val-Cit (Valine-Citrulline) with the potent tubulin inhibitor MMAD. This compound leverages the targeting capability of ADCs to deliver the cytotoxic agent MMAD specifically to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects.

MC-VA-PAB-Exatecan is a drug-linker conjugate used for synthesising ADCs, containing an ADC linker (MC-VA-PAB) and the topoisomerase I inhibitor Exatecan, which exhibits antitumour activity.

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

ABBV-969 Payload (Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT) is a drug-linker conjugate employed in the synthesis of antibody-drug conjugates (ADCs). The ABBV-969 Payload contains a Topoisomerase I inhibitor molecule and a chemical linker, enabling coupling with anti-c-Met antibodies to generate ABBV-969 ADCs with targeted anticancer activity.

Val-Ala-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), composed of the Val-Ala-PAB cleavable linker and MMAE, a potent microtubule inhibitor. It is designed to be cleaved by Cathepsin B within cancer cells, releasing MMAE to inhibit tubulin polymerization and induce apoptosis. This mechanism reduces toxicity to normal tissues while enhancing antitumor activity.

Mc-MMAD is monomethyl auristatin D (MMAD) modified with the protective group maleimidocaproyl (Mc). MMAD is a potent tubulin microtubule inhibitor that suppresses cancer cell proliferation and is commonly employed as a toxic payload in ADC synthesis.

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) consists of a cytotoxin, the topoisomerase I inhibitor DX-8951, and a linker sensitive to cathepsin, forming a drug-linker conjugate for antibody-drug conjugates (ADCs).

PSMA-ALB-56 is a PSMA-targeting radioactive ligand with antitumor activity, composed of glutamic urea PSMA binding entities, DOTA chelating agents, and albumin binders based on 4-(p-iodophenyl)- fragment or p(tolyl)- fragment.

Gly3-VC-PAB-MMAE A compound consisting of the ADC linker Gly3-VC-PAB and the microtubule inhibitor MMAE, which can be used to synthesize antibody-coupled reactive molecules.

DGN549-L is a DNA alkylator that enables antibody conjugation at lysine residues, making it ideal for antibody-drug conjugate (ADC) synthesis.

MC-GGFG-DX8951 (MC-GGFG-Exatecan) is an antibody-coupled drug (ADC) drug-linker conjugate (DLC) consisting of DX8951, a potent DNA topoisomerase I inhibitor, the linker MC, and the cleavable peptide chain GGFG, and has antitumor potential.

AminobenzenesulfonicauristatinE-d8 is a deuterated version of AminobenzenesulfonicauristatinE, which forms part of an antibody-drug conjugate. This compound is synthesized by linking the cytotoxic microtubule modifier Auristatin E with the ADC linker Aminobenzenesulfonic, endowing it with antitumor activity.

LNK2-S is a conjugate of the toxin molecule Exatecan and a linker, utilized in the synthesis of ADC (Antibody-Drug Conjugate) molecules.